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Atopic dermatitis is a disease with an impaired skin barrier that affects 15%–20% of children. In the normal epidermis,
the stratum corneum chymotryptic enzyme (SCCE) thought to play a central role in desquamation by cleaving proteins
of the stratum corneum (e.g., corneodesmosin and plakoglobin). Genetic variations within the SCCE gene could be
associated with dysregulation of SCCE activity leading to an abnormal skin barrier. We screened the SCCE gene for
variations and performed a case–control study on 103 atopic dermatitis patients and 261 matched controls. 16
synonymous single nucleotide polymorphisms (SNPs) have been identiﬁed and a 4 bp (AACC) insertion has been found
in the 30UTR. We performed an association study of the SCCE AACC insertion in the 30UTR, and found a signiﬁcant
trend between the AACC allele with the two insertions and disease in the overall data set [odds ratio (OR)¼ 2.31;
p¼ 0.0007]. The AACC insertion in the SCCE gene may result in a change to SCCE activity within the skin barrier.
These ﬁndings suggest that SCCE could have an important role in the development of atopic dermatitis.
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Several genes have been associated and/or linked to
increased IgE production  atopic dermatitis, including IL-
4 and the high-affinity IgE receptor (Cookson et al, 1989;
Marsh et al, 1994). We have previously demonstrated that
30% of children with clinically defined atopic dermatitis
have neither an elevated total nor specific IgE (Murphy et al,
1999). During the past fifty years, there have been several
changes in our environment, including increased exposure
to soap, detergents, and house dust mites (Williams, 1995;
Cork et al, 2002). Washing with soap reduces the thickness
and number of cell layers in the stratum corneum of normal
individuals and those with atopic eczema. This effect is
more pronounced in those with atopic dermatitis (Al-Jaberi
et al, 1984; White et al, 1987). The demonstration that up to
30% of children with clinically defined atopic dermatitis are
not immunologically atopic led us to hypothesize that
changes in genes that regulate the barrier function of the
skin would be very important in the development of atopic
dermatitis (Cork et al, 2002). These genetic changes could
render the skin barrier more vulnerable to breakdown by
environmental agents such as soap, detergents, and house
dust mite.
In the normal epidermis, the constant thickness of the
stratum corneum is maintained by a balance between the
proliferation of the keratinocytes in the basal layer and
desquamation from the surface of the stratum corneum
(Egelrud, 2000; Pierard et al, 2000). Corneodesmosomes
are structures involved in cohesion between the corneo-
cytes of the stratum corneum. Proteolysis of the corneo-
desmosomes is a crucial event prior to desquamation
(Lundstrom and Egelrud, 1988; Egelrud and Lundstrom,
1990). Stratum corneum chymotryptic enzyme (SCCE) is a
serine protease localized to the extracellular space of the
stratum corneum and is specific for keratinizing cells
undergoing desquamation (Egelrud and Lundstrom, 1991;
Egelrud, 1993; Sondell et al, 1994; Ekholm & Egelrud, 1998).
Apart from its tissue localization, SCCE has several
properties and characteristics, including its pH and inhibitor
profile of catalytic activity, matching the basic prerequisites
for a crucial involvement in desquamation under in vivo
conditions (Lundstrom & Egelrud, 1991; Egelrud et al, 1993;
Franzke et al, 1996). Transgenic mice overexpressing
human SCCE developed changes in their skin similar to
those seen in chronic atopic dermatitis (Hansson et al,
2002). The overexpression of SCCE initially may lead to a
premature breakdown of the epidermal barrier. This would
allow the penetration of irritants and allergens, which
triggers an inflammatory response, and subsequently a
reactive hyperplasia. The SCCE gene is therefore an
important candidate gene for atopic dermatitis. In this
study, we screened the coding region of the SCCE gene for
genetic variations and performed a disease case–control
association study in patients with atopic dermatitis.Abbreviation: SCCE, stratum corneum chymotryptic enzyme
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Results
To investigate the presence of polymorphisms in the SCCE
gene, we sequenced all 5 exons from both directions in 20
atopic dermatitis patients and 20 controls as described. We
identified a total of 17 polymorphisms, 12 in the introns, and
5 in the exons (Table 1). The first two were in exon 1, the
other three were in exon 5, with one being a 4 bp insertion
in the 30UTR. None of the exonic variants gave an amino
acid change. Sequence alignments, however, confirmed the
presence of a 4 bp insertion (AACC) in the 30UTR of the
SCCE gene of an atopic dermatitis patient (designated as
AE2). This is illustrated in Fig 1a, where the insertion is
shown as GGTT on the sequence of the chromatogram as
we used the reverse primer to sequence that specific
sample. For the purpose of clear illustration of the two-
repeat allele, we present another chromatogram obtained
from a control individual, where one can see the absence of
the second repeat (AACC) shown as GGTT on the reverse
sequence of the chromatogram (Fig 1b).
Based on the above discovery, a PCR-based assay was
designed, using specific primers that discriminate between
individuals that harbor the one-repeat (AACC) allele and
those that harbor the two-repeat (AACCAACC) allele. The
primers were designed such that they would be comple-
mentary to the DNA sequence, being exactly the same as
each other but with the difference that one of them would
miss the second repeat (AACC).
Based on the above optimization, we screened healthy
controls and atopic dermatitis patients in order to elucidate
the allelic distribution of the two distinct alleles of the
SCCE gene.
The allelic distribution of the SCCE AACC/AACCAACC
polymorphism in both atopic dermatitis and control groups
is shown in Table 2. There was a significant increase in the
frequency of rare allele (AACCAACC) in the patient group
(0.56) compared with the control group (0.43). As a dose
effect was evident for this polymorphism, the odds ratio
(OR) of homozygotes for the rare allele was significantly
greater than that of the heterozygous [OR 95% confidence
interval (CI) 2.32 (1.31,4.11) and 1.01 (0.57,1.79), respec-
tively]. Therefore, a w2 test for trend was carried out. A
significant association was found between SCCE- AAC-
CAACC variant and atopic dermatitis [OR¼ 2.31 (95% CI
(1.42, 3.76)); p¼0.0007] (Table 2).
We then stratified patients according to their IgE level,
elevated IgE (IgEelevated), and non-elevated IgE (IgEnon-
elevated), respectively. An elevated IgE was defined as raised
two standard deviations above the age-adjusted mean.
Interestingly, the OR increased in patients who did not
have an elevated IgEnon-elevated [(OR¼ 4.47 (1.49, 13.38));
p¼0.0039]. But the association was non-significant when
patients with an elevated IgE (IgEelevated) were analyzed
separately.
Discussion
In this study, we identified 17 SNPs within the SCCE gene, 5
of which are located in the exons (see Table 1). We have
demonstrated that homozygotes for the 30UTR 4-bp
insertion are more than two times more likely to develop
atopic dermatitis than individuals with the common allele. It
is important to emphasize that the control population of
adults contained a significant proportion of individuals who
would have had atopic dermatitis as a child (up to 15%),
suggesting that the risk for developing atopic dermatitis
reported here is underestimated.
We studied the 30UTR AACC insertion because we
believed that it could disturb the intercellular secondary
structure of the SCCE mRNA. It has been shown previously
that determinants of mRNA stability are frequently posi-
tioned in the 30UTR of the gene and any mutation could
affect the expression levels of the protein (Bilenoglu et al,
2002). The AACC insertion could increase the half-life of
SCCE mRNA, leading to an increased enzymatic activity of
SCCE. Interestingly, genetic variations and nucleotid acid
insertion in the 30UTR of genes encoding glycoprotein PC-1
and protein tyrosine phosphate 1B (PTP1B), encoding
inhibitors of the insulin signaling pathway have shown that
these variations stabilize PC-1 and PTP1B and increase
insulin resistance (Frittitta et al, 2001; Di Paola et al, 2002).
Subsequently, overexpression of SCCE would result in
enhanced proteolysis of the corneodesmosomal proteins,
producing a thin, defective epidermal barrier.
SCCE is capable of cleaving corneodesmosin (Cdsn) and
plakoglobin in vitro (Simon et al, 2001). The Cdsn (52–56
kDa) is involved in cohesion between corneocytes and its
proteolysis by SCCE leads to the production of different
proteolysis fragments (48–46, 36–30 and 15 kDa) (Simon
et al, 2001). This process takes place during differentiation
Table 1. Summary of polymorphisms found in SCCE (the bp
numbers are based on NCBI accession numbers






Exon 1(50UTR) 3230/09 G ! A
Exon 1 3290/69 G ! A
Intron 1 3310 A insertion
Intron 1 3346 G ! A
Intron 1 3419 G ! A
Intron 2 3879 G ! A
Intron 2 3902 A ! G
Intron 2 3908 G ! A
Intron 3 4980 G ! C
Intron 3 5004 C ! T
Intron 3 5041 C ! T
Intron 4 5340 G ! A
Intron 4 5409 T ! A
Intron 4 7327 A ! C
30UTR 7630/890 4 bp(AACC)
insertion/deletion
30UTR 7674/930 A ! G
30UTR 7687/943 A ! C
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of keratinocytes and an increase of SCCE activity could
enhance Cdsn proteolysis, and lead to an impaired
epidermal barrier as observed in the skin of patients with
atopic dermatitis.
We have previously reported that up to 30% of children
with clinically defined atopic dermatitis do not have a raised
non-specific or specific IgE, and are therefore not immu-
nologically atopic (Murphy et al, 1999). We postulated that a
primary genetically determined defect in the skin barrier
could explain the development of atopic dermatitis in these
children (Cork et al, 2002). Our findings of an association of
an AACC insertion in the 30UTR of the SCCE gene and
atopic dermatitis support this hypothesis. The observation
that the association of the SCCE AACC insertion was more
significant in the patients who did not have an elevated IgE
level is an important observation despite the small number
of patients with recorded IgE in this study (n¼30). A
defective epidermal barrier would allow the penetration of
both irritants and allergens, which may induce the produc-
tion of pro-inflammatory cytokines (e.g., TNF-a and IL-1a)
within the skin (Archer, 2000). This could result in the
development of eczematous lesions without the need for an
IgE-mediated inflammation. Specific allergens such as
DerP1 from house dust mites could also penetrate through
a defective epidermal barrier triggering a transient Th1 to
Th2 switch and specific IgE production. These IgE levels
may remain elevated for months or years but may have
returned to normal by the time IgE measurements were
made. A primary defect in the skin barrier could therefore
predispose to the development of eczematous lesions by
two mechanisms.
SCCE has also been proposed to be a candidate for
psoriasis and we have shown an increase in the amount of
both pro-SCCE and SCCE in lesional psoriatic skin com-
pared with non-lesional or normal skin (Simon et al, 2002). We
therefore tested the association of the SCCE 30UTR insertion
in a psoriatic cohort (n¼100) and found no significant
association between psoriasis and the SCCE 30UTR insertion
(data not shown). These findings suggest that SCCE is
unlikely to be involved in psoriasis and that the over-
expression of SCCE protein observed in lesional psoriatic
skin could be the consequence of an unspecific response to
hyperproliferation and inflammation in lesional skin.
Genome-wide scans have identified linkage to atopic
dermatitis on several chromosomes including 1q21, 17q25,
20p, and 3q21 (Lee et al, 2000; Cookson et al, 2001) but
none of these loci contains the SCCE gene, which is located
on 19q13.3. One explanation is that the effect of SCCE in
atopic dermatitis is too small to be detected by linkage.
Another explanation is that a high proportion of children with
atopic dermatitis included in these studies had an elevated
IgE level, which exceeded 70% in the Lee et al, 2000 study.
The power to detect a locus that may contain the SCCE
gene would be diluted since most of the association we
reported here was with patients who did not have an
elevated IgE level.
In conclusion, our findings indicate a statistically sig-
nificant association between an SCCE AACCAACC insertion
Figure1
Chromatograms of a control and an atopic dermatitis
30UTR sequences (a) Part of the chromatogram of the AE2
sequence (atopic dermatitis patient) that corresponds to exon
5 of the SCCE gene, from an atopic dermatitis patient. The
4 bp repeat is indicated by an arrow. (b) Part of the chro-
matogram of Poly9 (control) sequencewhere the second repeat
(AACC) is absent. The 4 bp single repeat, indicated by an
arrow, is shown as GGTT on the sequence of the chromato-
gram because we used the reverse primer to sequence the
purified PCR product.




Control 96 105 60 261
Atopic dermatitis
29 32 42 103
OR (95% CI) p-value Analysis performed
ORHET 1.01 (0.57, 1.79) NS —
ORHOM 2.32 (1.31, 4.11) 0.0037 —
OROVERALL 2.31 (1.42, 3.76) 0.0007 Trend (recessive model)
OROVERALL 1.48 (0.90, 2.44) NS Carriage (dominant model)
Heterozygotes, homozygotes, and overall data set odds ratios (ORHET, ORHOM and OROVERALL respectively) with 95% confidence intervals (CIs) for the
SCCE 30 UTR AACC insertion. Trend was carried out weighted by the number of putative disease susceptibility allele in each genotype group (recessive
model). For the dominant model, a carriage of AACCAACC allele was carried out.
NS, non-significant.
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and atopic dermatitis, which could play a central role in the
development of the disease. The effect of SCCE could be
more prominent in patients who do not have an elevated IgE
level. This suggests that in these patients a defective skin
barrier could be the primary event in the development of
atopic dermatitis. Further studies of SCCE mRNA and/or
protein, however, are required to strengthen the association
between SCCE and atopic dermatitis and to provide further
insights into the pathophysiological mechanisms of atopic
dermatitis.
Materials and Methods
Patient and control individuals The 103 atopic dermatitis
individuals who took part in this study were recruited from
dermatology clinics in Sheffield and Nottingham, UK following
approval from the local ethics committees. Each patient was
individually examined by an experienced dermatologist (M.J.C,
H.C.W, R.M) to confirm the diagnosis of atopic dermatitis and
provided informed consent to testing. The clinical diagnosis of
atopic dermatitis was made using the UK working party’s diagnostic
criteria for atopic dermatitis (Hanifin and Rajka, 1980; Williams et al,
1993, 1995). These criteria use only clinical assessments and do not
rely on IgE measurements. Morphology of the disease and family
history of atopy has also been considered. Using the Pharmacia
CAP system, total and specific serum IgE measurements to
common mixes of grasses, food, house dust mites, and animals
were made in all patients for whom there was total IgE data. IgE level
has been recorded for 30 atopy patients. IgE values in kU per liter
BS 75/502 are as calculated by the Sheffield Supraregional Assay
Service as shown in the protein reference unit (PRU) handbook
1993. The RASTscore was used for specific IgE measurements. The
specific IgE concentrations were measured in kU per liter (1 kU
being equal to 2.4 ng IgE) (WHO-IgE standard 75/502) and
expressed as a score (0–6, 0.35–100 kU per liter). Scores 0–1,
which correspond to RAST score for specific IgE measurements of
o0.35 and 0.35–0.7 units kU per liter, respectively, were classified
as patients with normal IgE level. Patients with specific IgE40.7 to
4100 units kU/l were classified as patients with an elevated IgE
level. An elevated total IgE was defined as a total serum IgE greater
than 2 standard deviations above the age-adjusted mean; this was
defined by the reference range from the Trent Regional Unit
Immunology Laboratory at the Northern General Hospital, Sheffield.
All individual patients with an elevated total IgE also had an elevation
of at least one of the specific IgE groups. Seven patients did not
have an elevated total IgE but did have an elevated non-specific IgE
level to one or more of the allergens in the 4 groups of animals,
grasses, dust mite, and foods tested (data not shown).
DNA from 261 healthy controls, ethnically matched to the
disease population (Caucasian, Northern English), used in this
study were obtained from blood donors from the Trent Blood
Transfusion service (Sheffield). Genomic DNA was extracted from
whole blood, obtained from the above individuals, using standard
protocols and stored in 96-well microtiter plates, with each well
containing 500 mL of DNA (100ng per mL).
SNP detection The exon–intron structure of SCCE was retrieved
from the NCBI database (accession number; AF166330). To
facilitate polymorphism analysis, we amplified all 5 exons of the
SCCE gene from 20 atopic dermatitis individuals and 20 controls in
separate polymerase chain reaction products, using the follow-
ing SCCE-specific primers: exon 1—forward 50GAATGCTTTCTCC-
TTCTCAGCTC30, reverse 50CGCAT CTCATCTGGGGAAC30, 601C;
exon 2—forward 50TGTCTCTGTCCATCTCTGACTCTGGGA30, re-
verse 50ACTGCCCTTCCACCCCCATAG30, 621C; exon 3—forward
50TGCACACCCTCTCTGTCACAG30, reverse 50TGTTGTTCAGGCT-
CCTGGTTCC30, 611C; exon 4—forward 50AGCCTGAACAACA-
GCCCT TCTG30, reverse 50GAGAATGAGGTGGAAAAAGCTGAG30,
601C; and exon 5—forward 50TCCCTAGCACT AGCTCTCCCA-
TTAG30, 50GAACGTCCAGTTCCAGTGTTTGAG30, 571C at 2mM
MgCl2 for all the exons. Amplification was achieved using Pfx
polymerase (Gibco, Paisley, UK), using 100 ng control or patient
DNA as template, in a 20 mL reaction in a 96-well Peltier thermal
cycler (MJ Research, Waltham, Massachusetts), under standard
conditions. Amplified products were run on a 1.5% agarose gel
and the desired bands were excised and purified using glasswool
tubes (Sigma). The purified DNA was sequenced using an ABI
Prism 377 DNA sequencer (Applied Biosystems, Foster City,
California). To detect possible polymorphisms, the resulting
sequences were compared with each other and with the corres-
ponding sequence of SCCE, using CLUSTALW (EBI; www.ebi.ac.
uk/CLUSTALW).
Genotyping For the allelic discrimination of the 4 bp (AACC)
insertion, two different primers were designed, one (I/DR1:
50GGTTTATCAACAGGGCAT GAGGTTTAAAT30, 611C) composed
of one AACC repeat and the other (I/DR2: 50GGTTTATCA-
ACAGGGCATGAGGTTGGTT30, 601C) with two AACC repeats.
The following PCR conditions were used: 2 ml Pfx polymerase
buffer (  1) (Gibco;  10), 1.0 mL MgSO4 (2.5 mM) (Gibco; 50
mM), 1.6 mL dNTPs (10 mM) (Promega, Southampton, UK), 2 mL
PCR enhancer solution (  1) (Gibco;  10), 0.06ml Pfx polymerase
(Gibco; 250 U), 1 mL primer F 50CACTAGCTCTCCCATTAGTCCCC30
(1.5 mM), 1 mL primer R (I/DR1 or I/DR2) (1.5 mM), 1 mL DNA
template (100 ng per mL), and 10.34 mL of sterile H2O, in a 96-well
Peltier thermal cycler (MJ Research), under the following condi-
tions: 981C for 5 min (1 cycle), 971C for 1 min, 60–611C for 30 s,
721C for 1 min (35 cycles), and 741C for 5 min and 41C hold. Three
hundred and sixty-four samples including 103 atopic dermatitis
patients and 261 controls have been genotyped for the SCCE
30UTR insertion. Possible genotyping errors have been considered
by re-typing 20% of the patients and control samples. We found
zero error.
Statistical analysis Disease and control groups were compared
using 2  3 tables. In the control group, the allelic distribution
of SCCE AACC allele/AACCAACC allele polymorphism was in
Hardy-Weinberg equilibrium. To investigate the possibility of a dose
effect, the odd ratios (ORs) for the heterozygotes and homozygotes
were calculated separately by comparing their risk with that for
individuals homozygous for the alternative allele. A dose effect was
evident because the ORs for the individual homozygous for the
rare allele (AACCAACC) were greater than individual heterozygous
for the same allele. Therefore, a w2 analysis for trend was carried
out, weighted by the number of putative susceptibility alleles in
each genotype group and Fisher’s exact p-value was calculated.
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